Source: Reuters (via feed)
India’s drug regulator has issued a warning to pharmaceutical companies regarding the advertising of weight-loss medicines. The warning includes both direct advertisements and surrogate promotions. Surrogate promotions involve obesity awareness campaigns that may act as indirect advertising of these drugs. The warning applies to global and domestic drugmakers. These companies are seeking to enter India’s growing market for obesity drugs.
BizTrendWire Insight:
The warning from India’s drug regulator addresses promotional activities related to weight-loss drugs. It covers direct marketing and indirect promotion through related campaigns.
The warning from India’s drug regulator addresses promotional activities related to weight-loss drugs. It covers direct marketing and indirect promotion through related campaigns.
